Cervomed Inc. has announced that neflamapimod, its investigational oral therapy, has achieved Phase 2b clinical proof-of-concept and is now progressing into a 24-week pivotal study for dementia with Lewy bodies $(DLB)$. The company highlights that DLB represents a significant and underserved global market. Preclinical studies demonstrated that neflamapimod reversed neurodegenerative processes in animal models, including improvements in cholinergic neuron function and behavioral outcomes. In the 16-week, placebo-controlled Phase 2a clinical trial (ASCEND-LB) involving 91 patients with DLB, neflamapimod significantly improved dementia severity and gait compared to placebo and reduced plasma biomarkers associated with neurodegeneration. The therapy showed a well-defined safety profile, with clinical safety data from over 700 volunteers and patients. You can access the full presentation through the link below.